Prostate Cancer

The evolving understanding of cancer genetics is allowing for clinicians to look at how to move rare cancer treatments, and identifications, forward.

The Food and Drug Administration noted the trial design was acceptable for researchers to evaluate VERU-111 in in metastatic castration and novel androgen-blocking agent resistant prostate cancer.

From the bi-partisan Research to Accelerate Cures and Equity (RACE) for Children Act implementing an FDA mandate that all new cancer therapies for adults must also be studied in children, to the “Iron Man” of baseball Cal Ripken Jr. announcing he’s cancer free after a February diagnosis, here’s what’s happening in the cancer landscape this week.

The World's Leading Non-profit Organization in Prostate Cancer Research Encourages Americans to Eat Healthier While Raising Awareness About Health Disparities Among African American Men.

New research has found that the risk for invasive prostate cancer increases significantly when patients have a family history of PBSIN along with invasive prostate cancer.

Prostate cancer treatments can cause side effects in a part of the body that might be unexpected— the heart. Here's how one expert believes patients can mitigate them. 

Researchers indicate that the current data suggest that race does not have a negative prognostic effect in patients with castration-resistant prostate cancer with bone metastases.

The risk for a major cardiovascular event was reduced by more than half in patients who received Relumina compared to the hormone associated therapy leuprolide.

“We don't know what the best treatment paradigm is for a patient whose disease is most clearly manifest on a PSMA scan as opposed to standard imaging,” said Dr. Michael J. Morris. “All that work has yet to be done, and we can only do it once we have the scan available to us as a tool in the United States.”

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for June 2020.

A PCF-funded study of men with prostate cancer in Italy suggests that men with prostate cancer who were taking ADT were 4 times less likely to be infected with the coronavirus than men who were not on ADT (androgen deprivation therapy), and 5 times less likely to die. These new findings are a game-changer and may lead to potential treatments for COVID-19, even in men without prostate cancer.

Immunotherapy could help a segment of patients with metastatic prostate cancer, a study found.

“On the basis of these results, (LuPSMA) appears to represent a new class of effective therapy for men with metastatic castration-resistant prostate cancer,” said Dr. Michael S. Hofman.

“These results provide compelling evidence for early darolutamide (Nubeqa) treatment in men with nonmetastatic CRPC,” lead study author Dr. Karim Fizazi, said in a virtual presentation during the meeting.

After a median follow-up of 15.8 months, patients within the mCRPC cohort who received the combination achieved an objective response rate of 33%.

The Food and Drug Administration’s approval of the PARP inhibitor Lynparza for patients with metastatic prostate cancer gives a smaller subgroup of patients another treatment option if hormonal therapies do not work.

The Food and Drug Administration gave the green light to the PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer that has a defective DNA-repair process and has progressed after treatment with the novel hormone-controlling drugs Xtandi (enzalutamide) or Zytiga (abiraterone acetate).

The PARP inhibitor Rubraca represents a new treatment option for men with metastatic castration-resistant prostate cancer that expresses a BRCA gene mutation and has been previously treated with hormonal therapy and taxane-based chemotherapy.

Obesity was associated with increased cardiovascular disease-related mortality and all-cause mortality, as well as potentially increased prostate cancer-specific mortality, in survivors of nonmetastatic prostate cancer.